- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.10. | Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More | 40 | Insider Monkey | ||
| 22.10. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10. | Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | 60 | GlobeNewswire (Europe) | -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and... ► Artikel lesen | |
| 14.10. | H.C. Wainwright senkt Kursziel für Inhibikase Therapeutics; behält Kaufempfehlung bei | 3 | Investing.com Deutsch | ||
| 14.10. | Inhibikase Therapeutics stock target cut by H.C. Wainwright; retains Buy rating | 1 | Investing.com | ||
| 09.10. | Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today | 1 | Benzinga.com | ||
| 09.10. | Inhibikase Therapeutics stock rises after pricing $110M private offering | 2 | Seeking Alpha | ||
| 09.10. | Inhibikase Therapeutics announces $110 million financing | 2 | Investing.com | ||
| 09.10. | Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension | 2 | GlobeNewswire (USA) | ||
| 09.10. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 16.08. | Inhibikase shares target cut, analyst retains buy rating on earnings report | 2 | Investing.com | ||
| 16.08. | Earnings call: Inhibikase Therapeutics reports Q2 financials, trial updates | 3 | Investing.com | ||
| 15.08. | Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01 | 1 | Seeking Alpha | ||
| 15.08. | Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary | 3 | Reuters | ||
| 14.08. | Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity | 84 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen | |
| 14.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 | 1 | GlobeNewswire (USA) | ||
| 06.08. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders | 2 | Seeking Alpha | ||
| 18.06. | Inhibikase Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 187,82 | +0,02 % | AbbVie: Übernahme | Der Pharma-Riese AbbVie verstärkt sich im Bereich der neurologischen Erkrankungen mit der milliardenschweren Übernahme von Aliada Therapeutics. Das Akquisitionsobjekt verfügt über eine hochinteressante... ► Artikel lesen | |
| TEVA | 17,000 | -0,29 % | PRESSESPIEGEL/Unternehmen: SAP, LILIUM, OLYMPUS, VARTA, RATIOPHARM, TECHEM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
SAP - Der Softwarekonzern SAP will sein Partnernetzwerk deutlich ausbauen.... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 10,675 | +0,95 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema | - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - - DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement... ► Artikel lesen | |
| BAUSCH HEALTH | 9,002 | -0,33 % | Bausch Health Companies Inc.: Bausch Health Announces Third Quarter 2024 Results | Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic... ► Artikel lesen | |
| ORGANIGRAM | 1,600 | -0,12 % | Paolo De Luca Sells 12,014 Shares of Organigram Holdings Inc. (TSE:OGI) Stock | ||
| QUANTUM BIOPHARMA | 4,920 | +19,42 % | Quantum Biopharma Ltd.: Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 in Australia | TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,200 | -2,86 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,139 | -4,61 % | Tonix berichtet über vielversprechende Daten zu Mpox-Impfstoffkandidat | ||
| NEWRON PHARMACEUTICALS | 8,870 | +3,50 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
| NEKTAR THERAPEUTICS | 1,125 | -0,53 % | Nektar Therapeutics: Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia | - Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) -
- Eight of nine patients achieved complete remission... ► Artikel lesen | |
| COMPASS PATHWAYS | 4,400 | -0,90 % | Compass Pathways plc: Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates | Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 101,75 | -0,15 % | Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 2024 | ||
| XORTX THERAPEUTICS | 1,270 | -9,61 % | Von XORTX gesponserte Studie wird während der American Society of Nephrology - Kidney Week 2024 präsentiert | Gesundheitliche Auswirkungen durch chronisch erhöhte Harnsäure und Xanthineoxidase bei Ratten, Mäusen und Menschen mit polyzystischer Nierenerkrankung
CALGARY, ALBERTA - 24. Oktober... ► Artikel lesen | |
| ENDO | - | - | Endo, Inc.: Endo Announces Successful Term Loan Repricing | MALVERN, Pa., Oct. 29, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 293,20 | -0,17 % | AKTIONÄR-Hot-Stock Madrigal Pharmaceuticals: Top-News - Aktie gewinnt 19 Prozent | Die Aktie des US-Biotech-Unternehmens Madrigal Pharmaceuticals kann am heutigen Handelstag einen satten Kurssprung hinlegen. Damit konnte nicht nur die jüngste Konsolidierung beendet, sondern sogar... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,81 % bei einem Aktienkurs von 2,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.
